Novo Nordisk stock faces FDA warning over rare vision risk
Published on 11/12/2026 at 12:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA warning puts safety risk in focus
- The FDA ordered label changes for all GLP-1 medicines after reviewing clinical, real-world and published evidence.
- Novo Nordisk says the available data do not establish a cause-and-effect relationship and maintains confidence in the benefit-risk profile of its medicines.
- The regulatory action adds a new investor consideration as the company seeks to sustain momentum in its obesity portfolio.
The U.S. Food and Drug Administration on Monday, November 9, required makers of GLP-1 medicines to add warnings about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. The rare eye condition can cause sudden vision loss, including permanent impairment. The decision affects Novo Nordisk's Wegovy and Ozempic as well as other GLP-1 medicines, according to CNBC.
Evidence remains rare and mixed
The FDA's review covered 126 clinical trials involving more than 134,000 patients. It identified 15 probable NAION events: 10 among GLP-1 users and five among placebo recipients. The analysis found 6.4 cases per 100,000 patient-years among GLP-1 users, compared with 3.8 cases among patients receiving other treatments or placebo.
The agency also reviewed real-world patient data and published studies. Some observational analyses indicated a higher risk compared with DPP-4 inhibitors, while the findings were not consistent against SGLT-2 inhibitors. The FDA said the available evidence points to a potential increased risk, but it has not established that GLP-1 medicines cause NAION.
Novo defends benefit-risk profile
Novo Nordisk said it continues to believe that the data do not establish a cause-and-effect relationship. The company said it remains confident in the benefit-risk profile of its GLP-1 medicines. Diabetes itself is a known risk factor for NAION, which makes it harder to separate the effect of the medicines from patients' underlying health conditions.
The labeling action creates an additional safety issue for investors to monitor alongside demand, pricing and competition in the obesity-drug market. Citi analysts cited by CNBC said the warning could briefly raise concern but should have limited impact on GLP-1 uptake because NAION is rare and the medicines have broader health benefits.
Novo Nordisk stock traded at 37.34 euros on Lang & Schwarz at 12:20 CET on Thursday, November 12, 2026.
Novo Nordisk at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Lang & Schwarz price: 37.34 euros at 12:20 CET on Thursday, November 12, 2026
- Regulatory issue: FDA warning requirement for a potential NAION risk
Investors can follow the broader European market through current market reports.
